Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will explore the effectiveness of low-dose aspirin on preventing pre-eclampsia in high-risks pregnant women by comparing the incidence of pre-eclampsia and pregnancy outcomes.
Currently,low-dose aspirin is a commonly used drug to prevent pre-eclampsia. Many guidelines recommend starting low-dose aspirin in early pregnancy in high-risks pregnant women. However, the applicable population and use method of aspirin are still controversial in clinical practice. This study will explore the effectiveness and use method of low-dose aspirin by comparing the incidence of pre-eclampsia and pregnancy outcomes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 75mg | Experimental | Take 75mg of aspirin daily in tihis group |
|
| 100mg | Active Comparator | Take 100mg of aspirin daily in this group |
|
| blank | No Intervention | Not taking aspirin in this group |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aspirin | Drug | For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of pre-eclampsia | Record the number of pre-eclampsia in each group and compare whether there are statistical differences in the incidence of each group | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Preterm birth | Record the number of preterm in each group and compare whether there are statistical differences in the incidence of each group | 1 year |
| Fetal growth restriction | Record the number of FGR in each group and compare whether there are statistical differences in the incidence of each group |
Not provided
Inclusion Criteria:
Age between 18-55 years
Gestational age between 12-20 weeks of pregnancy
High risk of developing pre-eclampsia
Maternal informed conset obtained
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fang He, Dr. | Contact | +86020-81292532 | hefangjnu@126.com |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Placental abruption 4/5000 Placental abruption | Record the number of placental abruption in each group and compare whether there are statistical differences in the incidence of each group | 1 year |
| Postpartum hemorrhage | Record the number of postpartum hemorrhage in each group and compare whether there are statistical differences in the incidence of each group | 1 year |
| D006841 |
| Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |